Linvoseltamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Linvoseltamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Linvoseltamab overview

Linvoseltamab (REGN-5458) is under development for the treatment of relapsed or refractory multiple myeloma. It acts by targeting cells expressing B-cell maturation antigen (BCMA) and CD3. The drug candidate is administered through intravenous route. It is a Bi-specific T-cell engager (BiTE)  monoclonal antibody being developed based on VelociGene and VelocImmune platform technology. It was also under development for the treatment of hematologic and solid tumors.

For a complete picture of Linvoseltamab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 3 November 2013

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.